Gout is the most common form of inflammatory arthritis and is a multifactorial disease typically characterized by hyperuricemia and monosodium urate crystal deposition predominantly in, but not limited to, the joints and the urinary tract. The prevalence of gout and hyperuricemia has increased in developed countries over the past two decades and research into the area has become progressively more active. We review the current field of knowledge with emphasis on active areas of hyperuricemia research including the underlying physiology, genetics and epidemiology, with a focus on studies which suggest association of hyperuricemia with common comorbidities including cardiovascular disease, renal insufficiency, metabolic syndrome and diabetes. Finally, we discuss current therapies and emerging drug discovery efforts aimed at delivering an optimized clinical treatment strategy.

PF-06372865 has a unique clinical pharmacology profile and a highly predictive translational data package from preclinical species to the clinical setting.

An advanced model-based control technique for regulating the blood glucose for patients with Type 1 diabetes is presented. The optimal insulin delivery rate is obtained off-line as an explicit function of the current blood glucose concentration of the patient by using novel parametric programming algorithms, developed at Imperial College London. The implementation of the optimal insulin delivery rate, therefore, requires simple function evaluation and minimal on-line computations. The proposed framework also addresses the uncertainty in the model due to interpatient and intrapatient variability by identifying the model parameters which ensure that a feasible control law can be obtained. The developments reported in this paper are expected to simplify the insulin delivery mechanism, thereby enhancing the quality of life of the patient.

No abstract

No abstract